GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Operating Income

ELAN (Elanco Animal Health) Operating Income : $253 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health Operating Income?

Elanco Animal Health's Operating Income for the three months ended in Sep. 2024 was $-5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $253 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Elanco Animal Health's Operating Income for the three months ended in Sep. 2024 was $-5 Mil. Elanco Animal Health's Revenue for the three months ended in Sep. 2024 was $1,030 Mil. Therefore, Elanco Animal Health's Operating Margin % for the quarter that ended in Sep. 2024 was -0.49%.

Elanco Animal Health's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Elanco Animal Health's annualized ROC % for the quarter that ended in Sep. 2024 was -0.10%. Elanco Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 84.81%.


Elanco Animal Health Operating Income Historical Data

The historical data trend for Elanco Animal Health's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health Operating Income Chart

Elanco Animal Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only 371.00 -82.00 304.00 384.00 326.00

Elanco Animal Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.00 10.00 133.00 115.00 -5.00

Elanco Animal Health Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $253 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elanco Animal Health  (NYSE:ELAN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Elanco Animal Health's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-20 * ( 1 - 34.88% )/( (13057 + 12534)/ 2 )
=-13.024/12795.5
=-0.10 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Elanco Animal Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2468/( ( (949 + max(2357, 0)) + (979 + max(1535, 0)) )/ 2 )
=2468/( ( 3306 + 2514 )/ 2 )
=2468/2910
=84.81 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(999 + 1611 + 904) - (291 + 356 + 510)
=2357

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(840 + 1632 + 340) - (259 + 333 + 685)
=1535

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Elanco Animal Health's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-5/1030
=-0.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Elanco Animal Health Operating Income Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanco Animal Health Business Description

Traded in Other Exchanges
Address
2500 Innovation Way, Greenfield, IN, USA, 46140
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Executives
Michael J Harrington director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jeffrey N Simmons director, officer: Pres., Chief Executive Officer 2500 INNOVATION WAY, GREENFIELD IN 46140
William F Doyle director
R David Hoover director C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Grace Mcardle officer: EVP, MANUFACTURING AND QUALITY 2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington officer: See remarks C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
John P Bilbrey director
Rajeev A. Modi officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen director C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brabander Ellen De officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger officer: Ex VP, Gen Counsel & Corp Sec C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia director 11690 N.W. 105TH STREET, MIAMI FL 33178
Uncas Gp Llc director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019

Elanco Animal Health Headlines

From GuruFocus